February 22, 2023 Breaking Down Barriers in Support of Patients with Rare Diseases You’re invited to join C-Path’s Gina Calarco Smith at the upcoming Breaking Down Barriers in Support of Ra
February 20, 2023 3rd PSTC Japan Safety Biomarker Workshop (presentations available) 2023 Presentations PMDA’s Perspective on the Evaluation of Novel Biomarkers (Hisanao Izumi, PhD) Biomolecular Needling System fo
February 17, 2023 C-Path Stands with Bruce Willis, Neurodegenerative Disease Community After FTD Diagnosis C-Path and its members stand with Bruce Willis and his family as they bravely revealed the difficult news of his Frontotemporal De
February 16, 2023 Leveraging the SCCM Discovery Virus COVID-19 Registry to Evaluate Drug Repurposing Research Dataset The CURE Repurposing Collaboratory (CDRC) partnered with the SCCM Discovery Virus COVID-19 Registry (Virus) to develop and build..
February 15, 2023 Airway Therapeutics Joins C-Path’s International Neonatal Consortium TUCSON, Ariz., February 15, 2023 — Critical Path Institute (C-Path) today announced that Airway Therapeutics, Inc. (“Airway”
February 14, 2023 Regulus Therapeutics Joins PKDOC C-Path is excited to announce that Regulus Therapeutics, Inc. has joined the Polycystic Kidney Disease Outcomes Consortium (PKD
February 8, 2023 TRxA 2023 Funding Opportunities C-Path's Translational Therapeutics Accelerator is a global drug discovery support program...
February 7, 2023 Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) Joins PKDOC C-Path is excited to announce that Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) has joined its Polycy
February 6, 2023 SARC Annual Meeting ASCO 2023 Leading into the annual meeting of the American Society of Clinical Oncology (ASCO), SARC will host the first of two 2023 SARC sem
January 25, 2023 C-Path Receives Letter of Support from EMA on Duchenne Muscular Dystrophy Clinical Trial Simulation Platform TUCSON, Ariz., Jan. 25, 2023 — Critical Path Institute (C-Path) today announced that the European Medicines Agency (EMA) has iss
